deferiprone has been researched along with Neurodegenerative Diseases in 14 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifteen postoperative patients with superficial siderosis were recruited, and seven patients were administered deferiprone (combination therapy group)." | 4.12 | Quantitative clinical and radiological recovery in post-operative patients with superficial siderosis by an iron chelator. ( Nose, Y; Sanjo, N; Sasaki, M; Tateishi, U; Uwano, I; Yokota, T, 2022) |
| "Deferiprone was well tolerated, and no serious adverse events occurred." | 2.76 | Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. ( Aquino, D; Bertini, E; Chiapparini, L; Garavaglia, B; Longo, F; Nardocci, N; Piga, A; Russo, L; Savoiardo, M; Solari, A; Zibordi, F; Zorzi, G, 2011) |
| "Deferiprone was shown to reverse iron deposition in Friedreich's ataxia." | 2.76 | A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. ( Abbruzzese, G; Balocco, M; Barella, S; Bonuccelli, U; Cossu, G; Forni, GL; Galanello, R; Marchese, R; Matta, G; Melis, M; Murgia, D; Ruffinengo, U, 2011) |
| "In one case, we managed to stabilize disease progression for more than 11 years." | 1.72 | Conservative Iron Chelation for Neuroferritinopathy. ( Defebvre, L; Devos, D; Huin, V; Kuchcinski, G; Marchand, F; Moreau, C, 2022) |
| "Neurodegenerative disorders, such as Alzheimer's disease (AD) and Parkinson disease (PD), can be considered as diverse pathological conditions sharing critical metabolic processes such as protein aggregation and oxidative stress." | 1.37 | Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease. ( Fakih, S; Francis, PT; Gaeta, A; Hider, RC; Kong, XL; Molina-Holgado, F; Salvage, S; Williams, RJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Gaeta, A | 1 |
| Molina-Holgado, F | 1 |
| Kong, XL | 1 |
| Salvage, S | 1 |
| Fakih, S | 1 |
| Francis, PT | 1 |
| Williams, RJ | 1 |
| Hider, RC | 1 |
| Nose, Y | 1 |
| Uwano, I | 1 |
| Tateishi, U | 1 |
| Sasaki, M | 1 |
| Yokota, T | 1 |
| Sanjo, N | 1 |
| Marchand, F | 1 |
| Moreau, C | 2 |
| Kuchcinski, G | 1 |
| Huin, V | 1 |
| Defebvre, L | 2 |
| Devos, D | 2 |
| Chen, S | 1 |
| Lai, X | 1 |
| Fu, J | 1 |
| Yang, J | 1 |
| Zhao, B | 1 |
| Shang, H | 1 |
| Huang, R | 1 |
| Chen, X | 1 |
| Kessler, RA | 1 |
| Li, X | 1 |
| Schwartz, K | 1 |
| Huang, H | 1 |
| Mealy, MA | 1 |
| Levy, M | 2 |
| Lemprière, S | 1 |
| Badat, M | 1 |
| Kaya, B | 1 |
| Telfer, P | 1 |
| Zhao, L | 1 |
| Hadziahmetovic, M | 1 |
| Wang, C | 1 |
| Xu, X | 1 |
| Song, Y | 1 |
| Jinnah, HA | 1 |
| Wodzinska, J | 1 |
| Iacovelli, J | 1 |
| Wolkow, N | 1 |
| Krajacic, P | 1 |
| Weissberger, AC | 1 |
| Connelly, J | 1 |
| Spino, M | 1 |
| Lee, MK | 1 |
| Connor, J | 1 |
| Giasson, B | 1 |
| Harris, ZL | 1 |
| Dunaief, JL | 1 |
| Bove, F | 1 |
| Fasano, A | 1 |
| Zorzi, G | 1 |
| Zibordi, F | 1 |
| Chiapparini, L | 1 |
| Bertini, E | 1 |
| Russo, L | 1 |
| Piga, A | 1 |
| Longo, F | 1 |
| Garavaglia, B | 1 |
| Aquino, D | 1 |
| Savoiardo, M | 1 |
| Solari, A | 1 |
| Nardocci, N | 1 |
| Abbruzzese, G | 1 |
| Cossu, G | 1 |
| Balocco, M | 1 |
| Marchese, R | 1 |
| Murgia, D | 1 |
| Melis, M | 1 |
| Galanello, R | 1 |
| Barella, S | 1 |
| Matta, G | 1 |
| Ruffinengo, U | 1 |
| Bonuccelli, U | 1 |
| Forni, GL | 1 |
| Kwiatkowski, A | 1 |
| Ryckewaert, G | 1 |
| Jissendi Tchofo, P | 1 |
| Vuillaume, I | 1 |
| Chinnery, PF | 1 |
| Destée, A | 1 |
| Hayflick, SJ | 1 |
| Hogarth, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)"[NCT00907283] | Phase 2 | 20 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| First Pilot Study Evaluating the Life Span of Autologous Cultured Red Blood Cells (cRBC) Generated From Peripheral Stem Cells in Three Healthy Volunteers - Feasibility Study[NCT00929266] | 1 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis[NCT02164253] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for deferiprone and Neurodegenerative Diseases
| Article | Year |
|---|---|
Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial.
Topics: Adolescent; Adult; Child; Deferiprone; Dose-Response Relationship, Drug; Female; Globus Pallidus; Hu | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.
Topics: Adult; Aged; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Ma | 2011 |
12 other studies available for deferiprone and Neurodegenerative Diseases
| Article | Year |
|---|---|
Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cells, Cultured; Humans; Hydrophobic | 2011 |
Quantitative clinical and radiological recovery in post-operative patients with superficial siderosis by an iron chelator.
Topics: Cerebellar Ataxia; Deferiprone; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Neurodege | 2022 |
Conservative Iron Chelation for Neuroferritinopathy.
Topics: Deferiprone; Disease Progression; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Neuroaxo | 2022 |
A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone.
Topics: Deferiprone; Humans; Iron; Membrane Proteins; Mitochondrial Proteins; Mutation; Neurodegenerative Di | 2023 |
Two-year observational study of deferiprone in superficial siderosis.
Topics: Adult; Aged; Aged, 80 and over; Brain; Deferiprone; Female; Hemosiderosis; Humans; Iron Chelating Ag | 2018 |
Ten years of iron chelation in a patient with superficial siderosis.
Topics: Aged; Deferiprone; Hemosiderosis; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Male; N | 2019 |
Drug reduces excess iron in ultra-rare neurodegenerative disease.
Topics: Deferiprone; Double-Blind Method; Humans; Iron; Neurodegenerative Diseases; Pantothenate Kinase-Asso | 2019 |
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; | 2015 |
Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.
Topics: Animals; Brain; Ceruloplasmin; Deferiprone; Disease Models, Animal; Iron; Iron Chelating Agents; Mem | 2015 |
Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
Topics: Ceruloplasmin; Chelation Therapy; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Met | 2015 |
Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation.
Topics: Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Middle Aged; Neurodegenerative Di | 2012 |
As iron goes, so goes disease?
Topics: Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Male; Neurodege | 2011 |